Atezolizumab

Cytostatic · Monoclonal antibody

Indications

Locally advanced or metastatic urothelial carcinoma, metastatic non-small cell lung cancer. Unresectable or metastatic alveolar soft part sarcoma (ASPS).

Dosage

Administer IV infusion over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes. Urothelial Carcinoma: As a single agent as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. NSCLC: In the adjuvant setting, administer following resection and up to 4 cycles of platinum-based chemotherapy as 840 mg every 2 weeks, 1200 mg every 3 weeks or 1680 mg every 4 weeks for up to 1 year. In the metastatic setting, administer as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. When administering with chemotherapy with or without bevacizumab, administer Atezolizumab prior to chemotherapy and Bevacizumab when given on the same day. Small Cell Lung Cancer: 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. When administering with carboplatin and etoposide, administer Atezolizumab prior to…

Administration

Administer the initial infusion over 60 mins through an IV line with or without a sterile, nonpyrogenic, low-protein binding in-line filter (pore size: 0.2-0.22 micron). Do not coadminister other drugs through the same IV line. Do not administer as an IV push or bolus. Reconstitution: To prepare soln for inf, withdraw 20 mL of atezolizumab from the vial. Dilute into a 250 mL polyvinyl chloride (PVC), polyethylene (PE), or polyolefin (PO) infusion bag containing 0.9% Sodium Chloride Injection. Dilute with 0.9% Sodium Chloride Injection only. Mix diluted solution by gentle inversion. Do not shake. Compatibility: Stable in NS. Stability: If diluted infusion soln is not used immediately, store soln either at room temp for no more than 6 hrs from the time of preparation. This includes room temp storage of the inf in the inf bag and time for adm of the inf, or under refrigeration at 2°C-8°C…

Adverse Effects

Nausea, vomiting, constipation, diarrhoea, fatigue, pyrexia, myalgia, arthralgia, cough, dyspnoea, peripheral oedema, pruritus, skin rash, decreased appetite, hematuria, UTI. Discontinue treatment in patients with severe infusion reactions.

Risk Factor (Pregnancy/Lactation)

Pregnancy: Contraindicated in pregnancy. Lactation: Contraindicated or not recommended. Precautions: Monitor thyroid function prior to and periodically during treatment. Monitor patients for sign and symptoms of hepatitis, pneumonitis, diarrhoea, colitis, adrenal insufficiency, hyperglycemia during treatment. Pregnancy should be avoided for 5 months after discontinuation of treatment.

Advice to Patient

If a dose is missed, it should be administered as soon as possible and administration schedule should be adjusted to maintain a 3-week interval between doses. Be cautious while driving and doing other skilled tasks that require alertness.

Pharmacokinetics

Half-life elimination: 27 days. Excretion: Clearance: 0.2 L/day.

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.